{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T05:28:51Z","timestamp":1663565331313},"reference-count":30,"publisher":"Informa Healthcare","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[1999,11]]},"DOI":"10.1517\/13543784.8.11.1893","type":"journal-article","created":{"date-parts":[[2005,5,4]],"date-time":"2005-05-04T18:15:34Z","timestamp":1115230534000},"page":"1893-1905","source":"Crossref","is-referenced-by-count":9,"title":["Eptifibatide: a potent inhibitor of the platelet receptor integrin, glycoprotein IIb\/IIIa"],"prefix":"10.1517","volume":"8","author":[{"given":"J Conor","family":"O\u2019Shea","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James E","family":"Tcheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3197","published-online":{"date-parts":[[2005,2,23]]},"reference":[{"key":"CIT0002","first-page":"39","volume":"68","author":"DEWOOD MA","year":"1983","journal-title":"Circulation"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)00276-2"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198405033101801"},{"key":"CIT0007","first-page":"799","volume":"71","author":"FALK E","year":"1985","journal-title":"Dynamic coronary thrombosis leading to infarction and\/or sudden death. Circulation"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199703203361207"},{"key":"CIT0012","first-page":"501","volume":"321","author":"HAAS WK","year":"1989","journal-title":"ADAMS HP JR et al.: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of strokes in high risk patients. N Engl. J. Merl."},{"key":"CIT0014","first-page":"301","volume":"31","author":"COLLER BS","year":"1994","journal-title":"Semin. Hematol"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1974.tb06660.x"},{"key":"CIT0016","first-page":"535","volume":"60","author":"PHILLIPS DR","year":"1977","journal-title":"Evidence for decreased amounts of two major glycoproteins. J. Clinic Invest."},{"key":"CIT0017","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1182\/blood.V58.2.268.268","volume":"58","author":"KUNICKI TJ","year":"1981","journal-title":"Blood"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199506083322306"},{"key":"CIT0019","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1182\/blood.V71.4.831.831","volume":"71","author":"PHILLIPS DR","year":"1988","journal-title":"Blood"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199404073301402"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03550060055036"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199706123362401"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(96)00749-7"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)10452-9"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1126\/science.2420006"},{"key":"CIT0028","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1182\/blood.V54.5.987.987","volume":"54","author":"MUSTARD JF","year":"1979","journal-title":"Blood"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.7.2471"},{"key":"CIT0031","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0021-9258(18)54042-4","volume":"268","author":"SCARBOROUGH RM","year":"1993","journal-title":"J. Biol. Chem."},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.5.6.595"},{"key":"CIT0035","first-page":"269","volume":"90","author":"UTHOFF K","year":"1994","journal-title":"Circulation"},{"key":"CIT0036","first-page":"2151","volume":"91","author":"TCHENG JE","year":"1995","journal-title":"Multicenter, randomized, double blind, placebo-controlled trial of the platelet integrin glycoprotein blocker Integrelin in elective coronary intervention. Circulation"},{"key":"CIT0037","first-page":"1222","volume":"76","author":"HARRINGTON RA","year":"1995","journal-title":"Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein Ilb\/IIIa inhibitor during percutaneous coronary intervention. Am. J. Cardiol."},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)10172-0"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808133390704"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.95.4.846"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.76.1.142"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.96.5.1488"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/13543784.8.11.1893","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T15:08:36Z","timestamp":1625929716000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1517\/13543784.8.11.1893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,11]]},"references-count":30,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2005,2,23]]},"published-print":{"date-parts":[[1999,11]]}},"alternative-id":["10.1517\/13543784.8.11.1893"],"URL":"https:\/\/doi.org\/10.1517\/13543784.8.11.1893","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,11]]}}}